NCT01598883View on ClinicalTrials.gov

"Understanding Heparin Resistance in Cardiac Surgery"

PHASE1CompletedINTERVENTIONAL

Enrollment

504

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions

Cardiopulmonary BypassAltered Heparin Response

Interventions

DRUG

Heparin

150 U/kg

DRUG

ATryn

1000 IU

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

rEVO Biologics

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT01598883 - "Understanding Heparin Resistance in Cardiac Surgery" | Biotech Hunter | Biotech Hunter